Aquestive Therapeutics, Inc. AQST Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s royalty — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported royalty — revenue of $0 in Q1 2026.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s royalty — revenue?
- Over 3 years (2021 to 2025), Aquestive Therapeutics, Inc.'s royalty — revenue has grown at a -5.2% compound annual growth rate (CAGR), from -$1.1M to $938K.
- What does royalty — revenue mean?
- This metric represents the total gross income recognized from intellectual property licensing agreements and royalty-bearing product sales within the specific business segment. It reflects the company's ability to monetize its proprietary technology and pharmaceutical formulations through third-party commercialization or partnership arrangements. Monitoring this revenue stream is essential for assessing the long-term value of the company's patent portfolio and the success of its out-licensing strategy.